TIGAR and esophageal squamous cell carcinoma: Furthermore, in these models, we have found that ESCC cells overexpressing TIGAR are more resistant to 5FU/DDP, the first-line chemotherapeutic agents routinely used to treat advanced or recurrent ESCC.